COVID-19封锁对肝切除术后并发症的影响:法国国家数据库倾向性评分匹配研究
基于法国国家出院数据库2019-2021年58,508例肝肿瘤住院患者,比较封锁期与2019、2021年同期的手术路径和术后结局。封锁期外科手术量下降11.6%,化疗考虑增多,但术后并发症(47% vs 47% vs 47%)和死亡率(3.3% vs 3.6% vs 3.1%)无显著差异;首次封锁期术后肺部并发症和感染性并发症显著高于第二次封锁期。
要点
- 封锁期肝肿瘤手术量下降11.6%,但术后并发症和死亡率与对照期相当。
- 首次封锁期术后肺部并发症(17% vs 13%)和感染性并发症(20% vs 15%)显著高于第二次封锁期。
- 封锁期更多患者在小体量中心手术(34% vs 32% vs 32%),高人口密度地区住院减少。
核心结论
- COVID-19封锁期间法国肝肿瘤外科手术量下降11.6%,但术后并发症和死亡率未受显著影响。
- 首次封锁期术后肺部并发症和感染性并发症显著高于第二次封锁期。
研究设计与样本
- 基于法国国家出院数据库的回顾性研究,纳入2019至2021年所有成人肝肿瘤住院患者,共58,508例。
- 封锁组18,907例,2019年对照组20,045例,2021年对照组19,556例,采用倾向性评分匹配比较临床路径和术后结局。
主要发现
- 封锁组手术患者1,514例(8.0%),2019年对照组1,514例(8.6%),2021年对照组1,466例(7.4%),P < .001。
- 术后并发症发生率三组均为47%(P = .90),死亡率分别为3.3%、3.6%、3.1%(P = .80)。
- 封锁对并发症的风险比=0.94(95%CI 0.81-1.09,P = .40),对死亡的比值比=1.12(95%CI 0.72-1.74,P = .6)。
- 首次封锁期术后肺部并发症17% vs 第二次13%(P = .024),感染性并发症20% vs 15%(P = .022)。
- 封锁期更多患者在小体量中心手术(34% vs 32% vs 32%,P = .034),高人口密度地区住院减少(P < .001)。
临床怎么用
- 封锁期间肝肿瘤手术可维持安全开展,术后并发症和死亡率与常态时期相当。
- 需关注首次封锁期较高的肺部及感染性并发症,加强围术期呼吸道和感染管理。
- 封锁期手术向小体量中心转移,应确保其围术期救治能力。
局限性
- 回顾性数据库研究,可能存在编码偏倚和未测量混杂因素。
- 仅反映法国医疗体系情况,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of the SARS-CoV-2 pandemic on managing liver malignancies worldwide is unknown. This study aimed to determine the impact of lockdowns on patient clinical pathways and postoperative morbi-mortality. METHODS: This study evaluated all adults' hospital stays for liver tumors between 2019 and 2021 from the national French discharge database. The primary outcome was the clinical pathway, especially surgical care and postoperative outcomes, between patients admitted during COVID-19 lockdown periods (lockdown group) and during the same periods of 2019 and 2021 (control groups). RESULTS: The overall population included 58,508 patients: 18,907 patients in the lockdown group, 20,045 in the 2019 control group, and 19,556 in the 2021 control group. Surgical activity decreased by 11.6% during lockdowns, with 1,514 (8.0%) of patients in the lockdown group treated by surgery, 1,514 (8.6%) in the 2019 control group (P < .001), and 1,466 (7.4%) in the 2021 control group. Chemotherapy was considered more during the lockdowns (P < .001). More patients were operated in small-volume centers during the lockdowns (34% vs 32% vs 32%, P = .034), and fewer were hospitalized in highly populated regions (P < .001). Postoperative morbidity (47% vs 47% vs 47%, P = .90) and mortality (3.3% vs 3.6% vs 3.1%, P = .80) were comparable in the 3 periods, with no influence of lockdowns on morbidity (risk ratio = 0.94, 95% confidence interval = 0.81-1.09, P = .40) or mortality (odds ratio = 1.12, 95% confidence interval = 0.72-1.74, P = .6). Postoperative pulmonary (17% vs 13%, P = .024) and septic complications (20% vs 15%, P = .022) were significantly higher during the first lockdown compared to the second. CONCLUSION: This study provides a French overview of liver malignancy management during the COVID-19 pandemic. Moreover, surgical activity decreased by 11.6% in high-volume centers, with no impact on postoperative morbidity and mortality.
引用
- Nassar A, Tzedakis S, Marchese U, et al. Impact of COVID-19 lockdowns on postoperative morbidity after hepatectomy: A propensity-score matching study on a national French database. Surgery. 2023. PMID: 37150714. doi:10.1016/j.surg.2023.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。